Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03882580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Study acronym: NEOCARDIO
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Mar 1, 2025 to Mar 1, 2030
    • Site details revised at 1 of 3 sites
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Publications: 1 to 2v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).
Trial Details
NCT Number NCT03882580
Lead Sponsor Groupe Hospitalier Pitie-Salpetriere
Conditions
(from sponsor)		 Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications, Cardiac Insufficiency, Metabolic Disorder, Vascular Disorder, Cardiac Disorder
Related terms Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Heart Diseases, Heart Failure, Metabolic Diseases, Vascular Diseases
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov